Clinical Trials Logo

Clinical Trial Summary

Currently there is no standard treatment for SARS-CoV-2 infection. Use of convalescent plasma has been studied in outbreaks of other respiratory infections, including SARS-CoV-1 , MERS-CoV and Hantavirus infection. This study is an open-label randomized trial in which patients with high risk of COVID19-associated respiratory failure will be randomized to early treatment with convalescent plasma (≤ 7 days from symptoms start) or at early signs of respiratory failure or prolonged hospitalization. COVID-19 convalescent plasma will be collected from individuals according to the institutional protocol.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04375098
Study type Interventional
Source Pontificia Universidad Catolica de Chile
Contact
Status Completed
Phase Phase 2
Start date May 4, 2020
Completion date August 17, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05543616 - A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children Phase 2/Phase 3
Recruiting NCT04516811 - Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 Phase 3
Completed NCT04334044 - Treatment of SARS Caused by COVID-19 With Ruxolitinib Phase 1/Phase 2
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Recruiting NCT04466241 - Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Phase 2/Phase 3
Withdrawn NCT04381923 - COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia N/A
Recruiting NCT04402879 - CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals N/A
Recruiting NCT04661631 - Surgery and Lung Ultrasound in COVID-19 Infection
Completed NCT04376476 - Host-pathogen Interactions During SARS-CoV-2 Infection N/A
Completed NCT04402060 - A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 Phase 1/Phase 2
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT04354779 - Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
Recruiting NCT04367207 - African Covid-19 Critical Care Outcomes Study
Terminated NCT04409873 - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) Phase 2
Completed NCT04602351 - Communication in ICU During COVID-19
Terminated NCT04707703 - Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis Phase 3
Active, not recruiting NCT04987528 - Pulmonary Fibrosis During Severe COVID-19 Pneumonia
Completed NCT04667936 - Evaluation of Sedation in COVID-19 ARDS
Completed NCT04423770 - COVID-19 Related Health and Infection Control Practices Among Dentists
Completed NCT04379037 - Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients N/A